Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Chromatin Remodeling Therapy and Capizzi Methotrexate in Treatment-Related MDS/AML

Catherine Aftandilian, MD, Kathleen M. Sakamoto, MD PhD, Kara L. Davis, DO, Gary Van Houten Dahl, MD, Norman J. Lacayo, MD

Blood (2018) 132 (Supplement 1): 5222.

https://doi.org/10.1182/blood-2018-99-110481

Published: 2018

Journal Articles

Comparison of the Transcriptomic Signature of Pediatric Vs. Adult CML and Normal Bone Marrow Stem Cells

Blood (2018) 132 (Supplement 1): 4246.

https://doi.org/10.1182/blood-2018-99-119974

Published: 2018

Journal Articles

Single Cell Network Profiling (SCNP) Signatures Predict Response to Induction Therapy and Relapse Risk In Pediatric Patients with Acute Myeloid Leukemia: Children's Oncology Group (COG) Study POG-9421

Norman J. Lacayo, MD, Aileen Cohen, Ph.D., M.D., Matt Westfall, Ph.D., Alan Lackey, MS, Xiaohua (Robert) Xin, Ph.D., M.D., Urte Gayko, Ph.D., Santosh Putta, Ph.D., Soheil Meshinchi, MD, PhD, Susana C. Raimondi, PhD, Todd A. Alonzo, PhD, Robert J. Arceci, MD, PhD, Yaddanapudi Ravindranath, MD, Gary Van Houten Dahl, MD, Alessandra Cesano, MD

Blood (2010) 116 (21): 954.

https://doi.org/10.1182/blood.V116.21.954.954

Published: 2010

Journal Articles

Excessive Cardiotoxicity Despite Excellent Leukemia-Free Survival for Pediatric Patients with Down Syndrome (DS) and Acute Myeloid Leukemia (AML): Results from POG (Pediatric Oncology Group) Protocol 9421.

Maureen O’Brien, MD, Jeffrey Taub, MD, Kimo Stine, MD, Myron Chang, Yaddanapudi Ravindranath, MD, David Becton, MD, Gary Van Houten Dahl, MD

Blood (2006) 108 (11): 559.

https://doi.org/10.1182/blood.V108.11.559.559

Published: 2006

Journal Articles

Forodesine in Patients with Refractory/Relapsed T-ALL Can Induce Prolonged Stable Remission with Minimal Toxicity before and after Allogeneic Hematopoietic Stem Cell Transplantation.

Mattias Stelljes, MD, Joachim Kienast, MD, Björna Berning, MD, Nicola Gokbuget, MD, Dieter Hoelzer, MD, Gerda Silling, MD, Wolfgang E. Berdel, MD, Gary Van Houten Dahl, MD, Debra Schissel, RN, Molly Hemenway, PNP, Lia Gore, MD

Blood (2006) 108 (11): 5340.

https://doi.org/10.1182/blood.V108.11.5340.5340

Published: 2006

Journal Articles

TBI and Allogeneic BMT Do Not Appear To Hinder Growth in Pediatirc Patients with AML Treated on POG 9421 (Now Children’s Oncology Group).

Kimo Stine, MD, David Becton, MD, Gary Van Houten Dahl, MD, Yaddanapudi Ravindranath, MD, Susana C. Raimondi, PhD, Fred Behm, MD, Myron Chang, Robert Arceci, MD

Blood (2006) 108 (11): 3677.

https://doi.org/10.1182/blood.V108.11.3677.3677

Published: 2006

Journal Articles

Gene Expression Profiling Predicts Outcome in De Novo Acute Myeloid Leukemia (AML) with Normal Karyotype: Results of Children’s Oncology Group (COG) Study POG #9421.

Norman J. Lacayo, MD, Maureen O’Brien, MD, Shweta Jain, Soheil Meshinchi, MD, PhD, Ron Yu, PhD, Dejan Juric, MD, Myron N. Chang, PhD, Robert Tibshirani, PhD, Yaddanapudi Ravindranath, MD, Howard J. Weinstein, MD, Branimir I. Sikic, MD, Gary Van Houten Dahl, MD

Blood (2006) 108 (11): 1915.

https://doi.org/10.1182/blood.V108.11.1915.1915

Published: 2006

Journal Articles

Novel Allele Quantification Method To Classify Childhood Leukemia.

Joshua D. Schiffman, MD, Hanlee Ji, MD, Katrina M. Welch, Ron Davis, PhD, Gary Van Houten Dahl, MD, Norman J. Lacayo, MD, James M. Ford, MD

Blood (2006) 108 (11): 2273.

https://doi.org/10.1182/blood.V108.11.2273.2273

Published: 2006

Journal Articles

Gene Expression Profiling and FLT3 Status Correlate with Outcome in De Novo Acute Myeloid Leukemia (AML) with Normal Karyotype: Results of Children’s Oncology Group (COG) Study POG #9421.

Norman Lacayo, MD, Soheil Meshinchi, MD, Susana Raimondi, PhD, Chitra Saraiya, MS, Maureen O’Brien, MD, Ronald Yu, PhD, Dejan Juric, MD, Myron Chang, PhD, Cheryl Willman, MD, Robert Tibshirani, PhD, Yaddanapudi Ravindranath, MD, Branimir Sikic, MD, Howard Weinstein, MD, Gary Van Houten Dahl, MD

Blood (2005) 106 (11): 2372.

https://doi.org/10.1182/blood.V106.11.2372.2372

Published: 2005

Journal Articles

Array CGH Discovers Novel Genomic Signatures in De Novo Acute Myeloid Leukemia (AML): Results of Children’s Oncology Group (COG) Study POG #9421.

Dennis J. Kuo, MD, Norman J. Lacayo, MD, Don Hoang, Dejan Juric, MD, Susana C. Raimondi, PhD, David Chen, Myron N. Chang, PhD, Yaddanapudi Ravindranath, MD, Howard J. Weinstein, MD, Branimir I. Sikic, MD, Gary Van Houten Dahl, MD

Blood (2005) 106 (11): 2771.

https://doi.org/10.1182/blood.V106.11.2771.2771

Published: 2005

Journal Articles

Genetic Randomization to Allogeneic Bone Marrow Transplant in First Remission Pediatric Acute Myeloid Leukemia Patients, Pediatric Oncology Group 9421 (Now Childrens Oncology Group).

Kimo Stine, MD, David Becton, MD, Gary Van Houten Dahl, MD, Yaddanapudi Ravindranath, MD, Susana C. Raimondi, PhD, Fred G. Behm, MD, Myron Chang, PhD, Howard Weinstein, MD

Blood (2004) 104 (11): 616.

https://doi.org/10.1182/blood.V104.11.616.616

Published: 2004

NARROW

Chromatin Remodeling Therapy and Capizzi Methotrexate in Treatment-Related MDS/AML

Comparison of the Transcriptomic Signature of Pediatric Vs. Adult CML and Normal Bone Marrow Stem Cells

Single Cell Network Profiling (SCNP) Signatures Predict Response to Induction Therapy and Relapse Risk In Pediatric Patients with Acute Myeloid Leukemia: Children's Oncology Group (COG) Study POG-9421

Excessive Cardiotoxicity Despite Excellent Leukemia-Free Survival for Pediatric Patients with Down Syndrome (DS) and Acute Myeloid Leukemia (AML): Results from POG (Pediatric Oncology Group) Protocol 9421.

Forodesine in Patients with Refractory/Relapsed T-ALL Can Induce Prolonged Stable Remission with Minimal Toxicity before and after Allogeneic Hematopoietic Stem Cell Transplantation.

TBI and Allogeneic BMT Do Not Appear To Hinder Growth in Pediatirc Patients with AML Treated on POG 9421 (Now Children’s Oncology Group).

Gene Expression Profiling Predicts Outcome in De Novo Acute Myeloid Leukemia (AML) with Normal Karyotype: Results of Children’s Oncology Group (COG) Study POG #9421.

Novel Allele Quantification Method To Classify Childhood Leukemia.

Gene Expression Profiling and FLT3 Status Correlate with Outcome in De Novo Acute Myeloid Leukemia (AML) with Normal Karyotype: Results of Children’s Oncology Group (COG) Study POG #9421.

Array CGH Discovers Novel Genomic Signatures in De Novo Acute Myeloid Leukemia (AML): Results of Children’s Oncology Group (COG) Study POG #9421.

Genetic Randomization to Allogeneic Bone Marrow Transplant in First Remission Pediatric Acute Myeloid Leukemia Patients, Pediatric Oncology Group 9421 (Now Childrens Oncology Group).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only